Activation of the A(2A) adenosine receptor inhibits nitric oxide production in glial cells

FEBS Letters

Volumn 429, Issue 2, 1998, Pages 139-142

  Brodie, Chaya ^a   Blumberg, Peter M ^b   Jacobson, Kenneth A ^c  

^a BAR ILAN UNIVERSITY   (Israel)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Human Motor Control Section   (United States)

Author keywords

Adenosine agonist; Adenosine receptor; C6 cell; Cytokine; Nitric oxide; Tumor necrosis factor

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; BUCLADESINE; CYCLIC AMP; FORSKOLIN; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; NOS2 PROTEIN, RAT;

ANIMAL CELL; ARTICLE; ASTROCYTE; BRAIN ISCHEMIA; CONTROLLED STUDY; GLIA CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYME INDUCTION; GLIA; METABOLISM;

ANIMALS; ENZYME INDUCTION; NEUROGLIA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032510829     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-5793(98)00556-0     Document Type: Article

References (27)

1. Eddleston M., Micke L. Neuroscience. 54:1993;15-36.
2. Simmons M.L., Murphy S. J. Neurochem. 59:1992;97-905.
3. Minc-Golomb D., Schwartz J.P. Trends Neurosci. 16:1993;323-328.
4. Hooper D.C., Ohnishi S.T., Kean R., Numagami Y., Dietzschold B., Koprowski H. Proc. Natl. Acad. Sci. USA. 92:1995;5312-5316.
5. Park S.K., Murphy S. J. Neurosci. Res. 39:1994;405-411.
6. Hu S., Sheng W.S., Peterson P.K., Chao C.C. Glia. 15:1995;491-494.
7. Simmons M.L., Murphy S. Eur. J. Neurosci. 5:1993;825-831.
8. Jacobson K.A., Suzuki F. Drug Dev. Res. 39:1997;289-300.
9. von Lubitz D.K.J.E., Beenhakker M., Lin R.-C., Carter M.F., Paul I.A., Bischofberger N., Jacobson K.A. Eur. J. Pharmacol. 302:1996;43-48.
10. von Lubitz D.K.J.E., Lin R.C.S., Popik P., Carter M.F., Jacobson K.A. Eur. J. Pharmacol. 263:1994;59-67.
11. Ogata T., Nakamura Y., Schubert P. Eur. J. Neurosci. 8:1996;1124-1131.
12. Peakman M.C., Hill S.J. Br. J. Pharmacol. 111:1994;191-198.
13. Murphy M.G., Moak C.M., Byczko Z., MacDonald W.F. J. Neurosci. Res. 30:1991;631-640.
14. Abbracchio M.P., Ceruti S., Brambilla R., Franceschi C., Malorni W., Jacobson K.A., von Lubitz D.K.J.E., Cattabeni F. Ann. N.Y. Acad. Sci. 825:1997;11-22.
15. Abbracchio M.P., Rainaldi G., Giammarioli A.M., Ceruti S., Brambilla R., Cattabeni F., Barbieri D., Franceschi C., Jacobson K.A., Malorni W. Biochem. Biophys. Res. Commun. 241:1997;297-304.
16. Fiebich B.L., Biber K., Gyufko K., Berger M., Bauer J., van Caulker D. J. Neurochem. 66:1996;1426-1431.
17. Mangoura D., Sakellaridis N., Jones J., Vernadakis A. Neurochem. Res. 14:1989;941-947.
18. Kim H.O., Ji X.-d., Siddiqi S.M., Olah M.E., Stiles G.L., Jacobson K.A. J. Med. Chem. 37:1994;3614-3621.
19. Jacobson K.A., Nikodijevic O., Padgett W., Gallo-Rodriguez C., Maillard M., Daly J.W. FEBS Lett. 323:1993;141-144.
20. Drapier J.C., Hibbs J.B. Eur. J. Immunol. 18:1988;1587-1592.
21. Brodie C., Goldreich G., Haiman T., Kazimirsky G. J. Neuroimmunol. 81:1998;20-30.
22. Frohman E.M., van den Noort S., Gupta S. J. Clin. Immunol. 9:1989;1-9.
23. Chao C.C., Molitor T.W., Hu S. J. Immunol. 151:1993;1473-1481.
24. Pahan K., Namboodiri A.M.S., Sheikh F.G., Smith B.T., Singh I. J. Biol. Chem. 272:1997;7786-7791.
25. Oda H., Toshihiko M., Nomura Y.J. Neurochemistry. 69:1997;669-674.
26. Dubey R.K., Gillespie E.K., Jackson E.K. Hypertension. 31:1998;296-302.
27. Jeffery S.R., Snyder S.H. Annu. Rev. Cell Dev. Biol. 11:1995;417-440.